No Data
No Data
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
Biogen, Eisai Say Injectable Alzheimer's Therapy Granted FDA Review
Reported Earlier, Eisai And Biogen Announced FDA Acceptance Of LEQEMBI BLA For Weekly Subcutaneous Dosing To Treat Early Alzheimer's Disease
BioArctic Partner's Biologics License Application for Subcutaneous Leqembi Gets US FDA Nod
Alzheimer's Drugs Market Report and Forecast 2024-2032, Competitive Analysis of F. Hoffmann-La Roche, Novartis, Merck Sharp & Dohme, Biogen, AbbVie, Eisai, J&J, Daiichi Sankyo, and Ono Pharma
Bernstein Keeps Their Buy Rating on Eisai Co (ESALF)
J Servai (JLAPT) : $Target Hospitality (TH.US)$ ...